



# Global Kidney Cancer Drug Market 2017 Share, Trend, Segmentation and Forecast to 2022

*Wiseguyreports.Com Adds "Kidney Cancer Drug - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 To 2022"*

PUNE, INDIA, May 24, 2017 /EINPresswire.com/ --  
Summary

This report studies the global [Kidney Cancer Drug](#) market, analyzes and researches the Kidney Cancer Drug development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Active Biotech  
Amgen  
Bayer AG  
Cipla Limited  
F. Hoffmann-La Roche  
Genentech  
Glaxosmithkline PLC  
Novartis AG  
Onyx Pharmaceuticals  
Pfizer  
Abbott Laboratories  
Aveo Pharmaceuticals  
Immatix Biotechnologies  
Prometheus Laboratories  
Exelixis

Request a Sample Report @ <https://www.wiseguyreports.com/sample-request/1256737-global-kidney-cancer-drug-market-size-status-and-forecast-2022>

Market segment by Regions/Countries, this report covers

United States  
EU  
Japan  
China  
India  
Southeast Asia

Market segment by Type, Kidney Cancer Drug can be split into

Nexavar (Sorafenib)  
Sutent (Sunitinib)  
Afinitor (Everolimus)  
Votrient (Pazopanib)  
Avastin (Bevacizumab)

Inlyta (Axitinib),  
Torisel (Temsirrolimus)  
Proleukin (Aldesleukin)  
Other

Market segment by Application, Kidney Cancer Drug can be split into  
Hospitals  
Clinics  
Research Center  
Other

At any Query @ <https://www.wiseguyreports.com/enquiry/1256737-global-kidney-cancer-drug-market-size-status-and-forecast-2022>

## Table of Contents

### Global Kidney Cancer Drug Market Size, Status and Forecast 2022

- 1 Industry Overview of Kidney Cancer Drug
  - 1.1 Kidney Cancer Drug Market Overview
    - 1.1.1 Kidney Cancer Drug Product Scope
    - 1.1.2 Market Status and Outlook
  - 1.2 Global Kidney Cancer Drug Market Size and Analysis by Regions
    - 1.2.1 United States
    - 1.2.2 EU
    - 1.2.3 Japan
    - 1.2.4 China
    - 1.2.5 India
    - 1.2.6 Southeast Asia
  - 1.3 Kidney Cancer Drug Market by Type
    - 1.3.1 Nexavar (Sorafenib)
    - 1.3.2 Sutent (Sunitinib)
    - 1.3.3 Afinitor (Everolimus)
    - 1.3.4 Votrient (Pazopanib)
    - 1.3.5 Avastin (Bevacizumab)
    - 1.3.6 Inlyta (Axitinib),
    - 1.3.7 Torisel (Temsirrolimus)
    - 1.3.8 Proleukin (Aldesleukin)
    - 1.3.9 Other
  - 1.4 Kidney Cancer Drug Market by End Users/Application
    - 1.4.1 Hospitals
    - 1.4.2 Clinics
    - 1.4.3 Research Center
    - 1.4.4 Other
- 2 Global Kidney Cancer Drug Competition Analysis by Players
  - 2.1 Kidney Cancer Drug Market Size (Value) by Players (2016 and 2017)
  - 2.2 Competitive Status and Trend
    - 2.2.1 Market Concentration Rate
    - 2.2.2 Product/Service Differences
    - 2.2.3 New Entrants
    - 2.2.4 The Technology Trends in Future

- 3 Company (Top Players) Profiles
  - 3.1 Active Biotech
    - 3.1.1 Company Profile
    - 3.1.2 Main Business/Business Overview
    - 3.1.3 Products, Services and Solutions
    - 3.1.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.1.5 Recent Developments
  - 3.2 Amgen
    - 3.2.1 Company Profile
    - 3.2.2 Main Business/Business Overview
    - 3.2.3 Products, Services and Solutions
    - 3.2.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.2.5 Recent Developments
  - 3.3 Bayer AG
    - 3.3.1 Company Profile
    - 3.3.2 Main Business/Business Overview
    - 3.3.3 Products, Services and Solutions
    - 3.3.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.3.5 Recent Developments
  - 3.4 Cipla Limited
    - 3.4.1 Company Profile
    - 3.4.2 Main Business/Business Overview
    - 3.4.3 Products, Services and Solutions
    - 3.4.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.4.5 Recent Developments
  - 3.5 F. Hoffmann-La Roche
    - 3.5.1 Company Profile
    - 3.5.2 Main Business/Business Overview
    - 3.5.3 Products, Services and Solutions
    - 3.5.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.5.5 Recent Developments
  - 3.6 Genentech
    - 3.6.1 Company Profile
    - 3.6.2 Main Business/Business Overview
    - 3.6.3 Products, Services and Solutions
    - 3.6.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.6.5 Recent Developments
  - 3.7 Glaxosmithkline PLC
    - 3.7.1 Company Profile
    - 3.7.2 Main Business/Business Overview
    - 3.7.3 Products, Services and Solutions
    - 3.7.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.7.5 Recent Developments
  - 3.8 Novartis AG
    - 3.8.1 Company Profile
    - 3.8.2 Main Business/Business Overview
    - 3.8.3 Products, Services and Solutions
    - 3.8.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
    - 3.8.5 Recent Developments
  - 3.9 Onyx Pharmaceuticals
    - 3.9.1 Company Profile
    - 3.9.2 Main Business/Business Overview

- 3.9.3 Products, Services and Solutions
- 3.9.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
- 3.9.5 Recent Developments
- 3.10 Pfizer
  - 3.10.1 Company Profile
  - 3.10.2 Main Business/Business Overview
  - 3.10.3 Products, Services and Solutions
  - 3.10.4 Kidney Cancer Drug Revenue (Value) (2012-2017)
  - 3.10.5 Recent Developments
- 3.11 Abbott Laboratories
- 3.12 Aveo Pharmaceuticals
- 3.13 Immatics Biotechnologies
- 3.14 Prometheus Laboratories
- 3.15 Exelixis

- 4 Global Kidney Cancer Drug Market Size by Type and Application (2012-2017)
  - 4.1 Global Kidney Cancer Drug Market Size by Type (2012-2017)
  - 4.2 Global Kidney Cancer Drug Market Size by Application (2012-2017)
  - 4.3 Potential Application of Kidney Cancer Drug in Future
  - 4.4 Top Consumer/End Users of Kidney Cancer Drug

...

Buy Now @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=1256737](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1256737)

Continued....

Norah Trent  
Wise Guy Consultants Pvt. Ltd.  
+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.